外周动脉疾病患者血小板反应性的性别差异
前瞻性队列研究纳入2020至2024年单中心261例外周动脉疾病血运重建患者,比较单抗与双抗治疗下血小板反应性的性别差异。单抗组女性纤维蛋白原相关血凝块强度更高、血小板聚集更强、血小板抑制更低,双抗组无性别差异。作者认为女性可能需要更积极抗血小板治疗。
要点
- 单抗组女性纤维蛋白原最大振幅25.5 mm vs 男性23.3 mm(P<0.002)。
- 单抗组女性血小板聚集93.0% vs 男性86.9%(P=0.009)。
- 单抗组女性血小板抑制3.9% vs 男性13.2%(P=0.009),双抗组无性别差异。
核心结论
- 单抗治疗组观察到血小板反应性的性别差异,作者认为女性可能需要更积极的抗血小板治疗以减少这一差异。
研究设计与样本
- 前瞻性队列研究,在单个大型三级中心纳入2020至2024年接受血运重建的外周动脉疾病患者。
- 共分析261例患者,35.2%为女性,88.9%为白人,74.1%接受单抗治疗。
- 按抗血小板治疗分为单抗组和双抗组,双抗包括阿司匹林联合氯吡格雷或替格瑞洛。
- 术前和术后采用血栓弹力图及血小板 Mapping 评估凝血轮廓。
- 采用曼-惠特尼 U 检验比较两性血小板功能差异,线性回归评估性别混杂效应,并做中介分析。
主要发现
- 单抗组女性纤维蛋白原相关血凝块强度(凝血因子纤维蛋白原最大振幅)为25.5 mm vs 男性23.3 mm(P<0.002)。
- 单抗组女性血小板聚集为93.0% vs 男性86.9%(P=0.009)。
- 单抗组女性血小板抑制为3.9% vs 男性13.2%(P=0.009)。
- 双抗组未观察到性别差异。
- 性别既未混杂也未中介抗血小板治疗对血栓弹力图参数的影响。
临床怎么用
- 作者认为,女性接受更积极的抗血小板治疗可能有助于减少单抗治疗下观察到的血小板反应性性别差异。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sex differences in platelet aggregation among peripheral artery disease patients are not well characterized. This study aimed to evaluate the impact of antiplatelet therapy on platelet reactivity by sex. METHODS: A prospective cohort study was conducted at a single large tertiary center on patients with peripheral artery disease undergoing revascularization between 2020 and 2024. Patients were stratified based on antiplatelet therapy (mono antiplatelet therapy [MAPT], or dual antiplatelet therapy [DAPT]), with DAPT including aspirin and clopidogrel/ticagrelor. Coagulation profiles, using thromboelastography (TEG) and platelet mapping, were assessed preoperatively and postoperatively. The Mann-Whitney U test was conducted to assess differences in platelet function between sexes. Linear regression models were used to assess the potential confounding effect of sex. Mediation analysis was also performed to determine if sex mediated the treatment's effect on TEG parameters. RESULTS: Of the 261 patients analyzed, 35.2% were women, 88.9% were Caucasian, and 74.1% were on MAPT. Women in the MAPT group had higher fibrinogen-related clot strength (coagulation factor fibrinogen maximum amplitude: 25.5 mm vs. 23.3 mm, P < 0.002), greater platelet aggregation (93.0% vs. 86.9%, P = 0.009), and lower platelet inhibition (3.9% vs. 13.2%, P = 0.009), whereas no sex differences were observed in the DAPT group. Sex neither confounded nor mediated the effect of antiplatelet therapy on TEG parameters. CONCLUSION: Sex differences in platelet reactivity were observed in the MAPT group, suggesting that more aggressive antiplatelet therapy in women may help reduce this disparity.
引用
- Rodriguez Alvarez AA, Cieri IF, Boya MN, et al. Sex Differences in Platelet Response to Common Antiplatelet Medications. Ann Vasc Surg. 2025. PMID: 40349837. doi:10.1016/j.avsg.2025.04.130
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。